Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

225.48 5.50 +2.50%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation (GKOS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Glaukos Corporation (GKOS) trades at a P/B ratio of 18.1×. Over the past ten years it has ranged from 0.0× (June 2015) to 20.3× (November 2026); the current reading is higher than 100% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 9.8× (4.58%)
FY2024 10.3× 27.57%
FY2023 8.1× 105.82%
FY2022 3.9× 11.79%
FY2021 3.5× (29.97%)
FY2020 5.0× 66.02%
FY2019 3.0× (73.51%)
FY2018 11.4× 69.37%
FY2017 6.7× (28.85%)
FY2016 9.5× 108.90%

Quarterly newest first

Period P/B ratio Change
Sep 2026 13.5× 12.33%
Jun 2026 12.0× 29.37%
Mar 2026 9.3× (5.39%)
Dec 2025 9.8× 61.79%
43 more quarters

Against its own ten years

Low 0.0× High 20.3×
Ten-year median 7.6×
Current reading's percentile 100

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on GKOS